Articles tagged with: Velcade
Erste Ergebnisse einer großen, direkten, klinischen Vergleichsstudie zeigen, dass rezidivierte Myelompatienten, die mit hochdosiertem Kyprolis und Dexamethason behandelt wurden, ein doppelt so langes progressionsfreies Überleben hatten im Vergleich zu rezidivierten Patienten, die mit Velcade und Dexamethason behandelt wurden.
Das mittlere progressionsfreie Überleben in der Phase 3-Studie betrug 18,7 Monate bei den mit hoch dosiertem Kyprolis (Carfilzomib) und Dexamethason behandelten Studienteilnehmern im Vergleich zu 9,4 Monaten bei Patienten, die Velcade (Bortezomib) und Dexamethason erhielten.
Die Ergebnisse der so genannten "ENDEAVOR"-Studie wurden am letzten Sonntagabend in einer von Amgen (NASDAQ:AMGN) herausgegebenen Presseinformation …
Initial results of a large, head-to-head clinical trial show that relapsed myeloma patients treated with high-dose Kyprolis and dexamethasone had twice the progression-free survival of relapsed patients treated with Velcade and dexamethasone.
Median progression-free survival in the Phase 3 trial was 18.7 months in trial participants treated with high-dose Kyprolis (carfilzomib) and dexamethasone (Decadron), compared to 9.4 months in patients treated with Velcade (bortezomib) and dexamethasone.
The results of the so-called “ENDEAVOR” trial were announced this past Sunday evening in a press release issued …
Results of a small preclinical study conducted at the Karmanos Cancer Center in Detroit indicate that the oral anesthetic dyclonine may enhance the anti-myeloma activity of Velcade.
Dyclonine is the active ingredient in the Sucrets brand of sore throat lozenges, which are sold over-the-counter in drugstores and other retailers in Canada and the United States. Sucrets lozenges are marketed by Insight Pharmaceuticals.
The Karmanos researchers conducted laboratory tests of dyclonine's activity against the so-called "RPMI8226" line of myeloma cells, which is commonly used in pre-clinical testing of potential myeloma therapies. …
French researchers earlier this week published updated results of a small Phase 2 clinical trial testing the combination of Revlimid, Velcade, and dexamethasone (RVD) in newly diagnosed multiple myeloma patients.
The researchers found that RVD, when given before and after stem cell transplantation – and when followed by maintenance therapy with Revlimid – led to very deep treatment responses and significant survival rates.
The 31 newly diagnosed patients in the French trial initially were treated with three cycles of RVD therapy. Next, the trial participants underwent autologous (own) stem cell …
This year’s American Society of Clinical Oncology (ASCO) annual meeting in Chicago ended last Tuesday.
The day before the meeting ended was the busiest day at the meeting with regard to myeloma research. It featured a session of oral presentations in the morning and a poster session in the afternoon. In addition, an education session was held in the afternoon that included one myeloma-related talk, given by Dr. Leif Bergsagel of the Mayo Clinic, about progress in the treatment of multiple myeloma (article in the ASCO 2014 Educational Book). …